Tekmira

Maxim Maintains Buy On Tekmira Pharma As HBV Antisense Therapy Moves Into The Clinic

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $27 price …

Ben Mahaney, Editor — January 21, 2015, 6:14 PM EDT